Loading market data...
Sat, 13 Jun 2026
05:36:57 am
Sat, 13 Jun 2026
05:36:57 am
Rudransh Sangwan
Published at: June 12, 2026, 10:37 AM
Synopsis
Emcure Pharmaceuticals reported a strong FY26 performance with revenue rising 16.6% YoY to ₹9,204 crore and profit after tax increasing 33.1% to ₹941 crore. International markets remained the key growth driver, while EBITDA expanded 21.8% to ₹1,789 crore with margins improving to 19.4%. Strategic acquisitions, in-licensing partnerships, and a robust product pipeline further strengthened the company's long-term growth outlook.
Emcure Pharmaceuticals reported a solid financial performance for FY26, driven by strong international market expansion, improving operational efficiency, and strategic portfolio enhancements.
The company reported revenue from operations of ₹9,204 crore, compared to ₹7,896 crore in FY25, representing a 16.6% year-on-year growth. Profit after tax (PAT) rose 33.1% YoY to ₹941 crore, while adjusted PAT increased 40.9% to ₹1,008 crore.
The performance reflects strong demand across key therapeutic segments, growing international market penetration, and higher contribution from differentiated products.
| Metric | FY26 | FY25 | YoY Growth |
|---|---|---|---|
| Revenue from Operations | ₹9,204 Cr | ₹7,896 Cr | +16.6% |
| EBITDA | ₹1,789 Cr | ₹1,469 Cr | +21.8% |
| EBITDA Margin | 19.4% | 18.6% | +83 Bps |
| Profit After Tax (PAT) | ₹941 Cr | ₹707 Cr | +33.1% |
| Adjusted PAT | ₹1,008 Cr | ₹715 Cr | +40.9% |
| Net Profit Margin | 10.2% | 8.9% | +127 Bps |
| ROCE | 23.8% | 22.0% | +180 Bps |
Loading chart...
The expansion in profitability was supported by productivity improvements, better operating leverage, and increased contribution from higher-margin in-house products.
International markets continued to be the largest contributor to Emcure's growth during FY26.
| Segment | FY26 Revenue | Growth |
|---|---|---|
| International Business | ₹5,177 Cr | +22.2% |
| Domestic Business | ₹4,027 Cr | +10.0% |
| Total Revenue | ₹9,204 Cr | +16.6% |
International revenue contributed approximately 56% of total revenue, highlighting the company's growing global footprint.
Emcure reported strong growth across key international geographies.
| Region | FY26 Revenue | YoY Growth |
|---|---|---|
| Europe | ₹1,850 Cr | +25.5% |
| Canada | ₹1,487 Cr | +18.7% |
| Rest of World (RoW) | ₹1,840 Cr | +21.8% |
The strong performance was supported by increased market penetration, product launches, and expansion of existing portfolios.
The domestic business recorded 10% growth during FY26, broadly in line with the Indian Pharmaceutical Market (IPM).
Growth was primarily driven by:
Management indicated continued momentum across high-growth therapeutic categories.
Emcure made several strategic moves during FY26 to strengthen its long-term growth platform.
The company acquired full ownership of Zuventus Healthcare by purchasing the minority stake for ₹724.9 crore, further consolidating its domestic business operations.
Emcure expanded its product portfolio through partnerships with:
These collaborations are expected to strengthen the company's specialty and chronic care offerings.
The company's UK subsidiary, Tillomed Laboratories, signed a £19.7 million asset purchase agreement, supporting its international expansion strategy.
Emcure continues to invest in differentiated pharmaceutical products across multiple high-growth categories.
Management believes these segments will play a critical role in driving future revenue growth and margin expansion.
The company maintained a healthy financial profile despite significant investments during the year.
| Metric | FY26 |
|---|---|
| Gross Debt | ₹1,204 Cr |
| Net Debt | ₹1,054 Cr |
| Operating Cash Flow | ₹944 Cr |
| FY25 Operating Cash Flow | ₹852 Cr |
Cash generation improved significantly during FY26, reflecting stronger profitability and operational efficiency.
However, investing cash outflows increased primarily due to:
Emcure remains focused on:
The company expects continued growth across domestic and international markets, supported by its diversified portfolio and strong product pipeline.
Emcure Pharmaceuticals Limited is one of India's leading pharmaceutical companies with a strong presence across domestic and international markets.
The company operates across multiple therapeutic areas including:
Emcure exports products to numerous global markets and continues to expand its footprint through acquisitions, partnerships, and product innovation.
Emcure Pharmaceuticals delivered a strong FY26 performance, with double-digit revenue growth, significant margin expansion, and robust profitability improvement. International markets remained the primary growth driver, while strategic acquisitions and global partnerships enhanced the company's competitive position.
With a growing biologics pipeline, expanding international presence, and stronger operational efficiency, Emcure appears well-positioned to capitalize on long-term opportunities in both domestic and global pharmaceutical markets.
The company reported revenue from operations of ₹9,204 crore, up 16.6% YoY.
Profit after tax (PAT) increased 33.1% to ₹941 crore.
EBITDA rose 21.8% YoY to ₹1,789 crore.
Europe was the fastest-growing major region, with revenue increasing 25.5% to ₹1,850 crore.
The company acquired full control of Zuventus Healthcare through a ₹724.9 crore transaction.
Key growth drivers include biologics, complex injectables, NDDS products, international expansion, and strategic in-licensing partnerships.
Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
NFP Sampoorna Foods Limited reported a strong FY26 performance, with revenue from operations rising 43.28% YoY to ₹51.06 crore, EBITDA surging 96.
Felix Industries FY26 results: Net profit jumps 99.5% to ₹18.18 crore, revenue surges 178% to ₹102.21 crore, and EBITDA more than doubles.
HDFC Bank witnessed 15 NSE block deals worth over ₹622 crore involving more than 83 lakh shares.
Zee Entertainment shares jump 4% after board approves ₹2,300 crore fundraising plan. Explore stock performance, Q4 results, growth strategy,...
APAR Industries FY26 results: Revenue rises to ₹22,902 crore, PAT reaches ₹977 crore, U.S. revenue target set at ₹4,800 crore, and ₹1,500 crore capex...
